Tonix Pharmaceuticals Holding Corp.
$10.87
-$0.55 (-4.82%)
$10.80Day Range$11.47
Key Statistics
Market Cap
$186.43M
Shares Outstanding
17.2M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Feb 13, 2009
Round Lot
100
Locale
US
Trading Data
Day Open
$11.43
Day High
$11.47
Day Low
$10.80
Volume
808.5K
VWAP
$11.00
Prev Close
$11.42
Transactions
--
Acc. Volume
--
About Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
PHARMACEUTICAL PREPARATIONSSIC 2834142 employees200 CONNELL DRIVE, SUITE 3100, BERKELEY HEIGHTS, NJ, 07922212-980-9155IPO Feb 13, 2009US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001430306
- Composite FIGI
- BBG000LG8XM5
- Share Class FIGI
- BBG001T49NZ9
- Ticker Root
- TNXP
- SIC Code
- 2834
About Tonix Pharmaceuticals Holding Corp. (TNXP) Stock
Tonix Pharmaceuticals Holding Corp. (TNXP) closed the 2026-09-18 session at $10.87, down 4.82% versus the previous close (-0.55). The stock opened at $11.43 and traded between $10.80 and $11.47 during that session. Session trading volume was 808K shares. The volume-weighted average price (VWAP) is $11.00.
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
Tonix Pharmaceuticals Holding Corp. has a market capitalization of $186.4 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. TNXP is listed on the XNAS exchange. The company employs approximately 142 people. Tonix Pharmaceuticals Holding Corp. is headquartered in BERKELEY HEIGHTS, NJ. The recorded listing date is 2009-02-13.
On this page you can find market TNXP stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.